QAE 397

Drug Profile

QAE 397

Alternative Names: QAE397

Latest Information Update: 12 Jul 2011

Price : $50

At a glance

  • Originator Novartis
  • Class Antirheumatics; Corticosteroids
  • Mechanism of Action Undefined mechanism
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.


Highest Development Phases

  • Discontinued Asthma; Chronic obstructive pulmonary disease

Most Recent Events

  • 29 Jun 2011 Discontinued - Phase-II for Asthma in Italy (Inhalation)
  • 28 Jul 2010 No development reported - Phase-II for Asthma in Italy (Inhalation)
  • 19 Jan 2006 Discontinued - Phase-I for Chronic obstructive pulmonary disease (unspecified route)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at so we can help.

Back to top